Ferring
Ferring Pharmaceuticals is a global biopharmaceutical company dedicated to innovative healthcare solutions. Their mission is to improve the quality of life for patients worldwide through research, development, and collaboration in various medical fields including reproductive medicine, gastroenterology, urology, and more. They are committed to helping people build families and live better lives, with a focus on research-driven, specialty biopharmaceuticals. The company emphasizes scientific innovation, ethical practices, and making a difference in patients' lives. Ferring has a strong presence in multiple countries and continuously invests in research, clinical trials, and expanding their manufacturing capabilities, including new facilities for gene therapy and other advanced treatments.
Industries
Nr. of Employees
Very Large (1000+)
Ferring
Ferring Pharmaceuticals, 25, Rue des Forges, 1700 Fribourg, Switzerland
Services
Collaborative agreements to co-develop discovery programs and share resources across early stages of drug development.
Operational and governance support for late-stage collaborations to advance near-market assets with external partners.
Operational support for clinical study design, execution and pipeline coordination across development stages.
On-site drug-product manufacturing capacity for gene therapy programs, including regional production sites to support supply continuity.
Directory service to identify country-specific contact points and local information for operations and enquiries.
Design and execution of observational and post-marketing studies to assess long-term safety and effectiveness of therapies in routine clinical practice.
Collaborative agreements to co-develop discovery programs and share resources across early stages of drug development.
Operational and governance support for late-stage collaborations to advance near-market assets with external partners.
Operational support for clinical study design, execution and pipeline coordination across development stages.
On-site drug-product manufacturing capacity for gene therapy programs, including regional production sites to support supply continuity.
Directory service to identify country-specific contact points and local information for operations and enquiries.
Design and execution of observational and post-marketing studies to assess long-term safety and effectiveness of therapies in routine clinical practice.
Expertise Areas
- Clinical trial management
- Drug discovery and early clinical development
- Translational research methodologies
- Reproductive medicine and maternal health research
Key Technologies
- Clinical trial platforms and protocols
- Preclinical and early clinical development methods
- Drug discovery workflows
- Microbiome research methods
News & Updates
Ferring's Commitment to Sustainability
Ferring emphasizes its commitment to sustainability, reducing inequalities, and protecting women and families.
Ferring's Research and Development Initiatives
Updates on Ferring’s research areas, clinical trials, and collaborations in drug discovery.
Ferring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of individualised vs.conventional recombinant follicular stimulating hormone dosing in Indian infertile patients
Data presented at the ASPIRE congress demonstrate higher pregnancy and live birth rates for Rekovelle® (follitropin delta).
U.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)
Expansion of production capacity with new Parsippany, NJ, facility, ensuring supply and manufacturing diversification.
Ferring publishes 2024 Annual Report & Sustainability Report
Ferring's financial and sustainability achievements for 2024.
Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility
New manufacturing facility in Europe to support gene therapy treatments.
Ferring's Commitment to Sustainability
Ferring emphasizes its commitment to sustainability, reducing inequalities, and protecting women and families.
Ferring's Research and Development Initiatives
Updates on Ferring’s research areas, clinical trials, and collaborations in drug discovery.
Ferring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of individualised vs.conventional recombinant follicular stimulating hormone dosing in Indian infertile patients
Data presented at the ASPIRE congress demonstrate higher pregnancy and live birth rates for Rekovelle® (follitropin delta).
U.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)
Expansion of production capacity with new Parsippany, NJ, facility, ensuring supply and manufacturing diversification.
Ferring publishes 2024 Annual Report & Sustainability Report
Ferring's financial and sustainability achievements for 2024.
Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility
New manufacturing facility in Europe to support gene therapy treatments.